logo
RTX delivers first radar to MDA that can track hypersonic weapons

RTX delivers first radar to MDA that can track hypersonic weapons

Yahoo20-05-2025

Raytheon has delivered the first missile defense radar to the Missile Defense Agency upgraded with the capability to track hypersonic weapons, the company announced Monday.
The MDA has long used AN/TPY-2 radars to track ballistic missiles, but this new version features a Gallium Nitride, or GaN, populated array, Raytheon said.
The new AN/TPY-2 X-band radar is the 13th system to be delivered to the agency but the first with the technology. It will be a part of the U.S. Army's eighth Terminal High Altitude Area Defense battery.
The radars can be used in a forward-based mode, providing cuing data to systems like the U.S. Navy's Aegis ballistic missile defense system or the Army's Patriot missile defense system. It serves as the primary radar for the Army's THAAD system.
GaN is technology already integrated into the Army's Lower-Tier Air and Missile Defense System radar, which was approved for low-rate production last month and will serve as the new tracking sensor for the Patriot air-and-missile defense system.
Raytheon has its own GaN foundry in Andover, Massachusetts, and has worked to develop the capability over decades that allows the radar to run 'at twice the power that we had before,' John Norman, company vice president of requirements and capabilities for Raytheon Air and Space Defense Systems, told Defense News.
'You have twice the sensitivity, twice the range. It's just incredibly efficient,' he said. 'Now we're able to see those targets coming in, to be able to discriminate.'
GaN allows for greater fidelity to see when a warhead separates from a missile body, as well as whether there are decoys present.
'You're going to have much greater target specificity,' Norman added.
Hypersonic threats fly at speeds greater than Mach 5 and are maneuverable in the glide phase of flight, making them very difficult to track. This means it's important to defeat hypersonic weapons earlier in flight at greater ranges.
The new radar is 'going to enable them to fire at those targets earlier in the engagement cycle,' Norman said.
The technology also has a longer time in between failures or maintenance needs.
'This is just operational more often,' Norman said. 'That resolves like 90% of the angst that we had doing that mission set because the missiles are always there, the firing batteries are always there, but it's having the sensors to make sure you have the coverage of the area you're trying to defend.'
While MDA is the first U.S. entity to receive the AN/TPY-2 radar with GaN, Saudi Arabia was the first to receive the upgraded version, according to Norman.
Raytheon is now working with the Army on how to take advantage of the company's investments to upgrade the systems it has in operation. They're also trying to address other modernization needs, such as integrating new computer components and signal data processing equipment to free up space in the electronics unit, which will make sustainment and maintenance easier, according to Norman.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Regeneron price target lowered to $650 from $700 at Citi
Regeneron price target lowered to $650 from $700 at Citi

Business Insider

time2 hours ago

  • Business Insider

Regeneron price target lowered to $650 from $700 at Citi

Citi analyst Geoff Meacham lowered the firm's price target on Regeneron (REGN) to $650 from $700 and keeps a Buy rating on the shares. The company reported mixed itepekimab Phase 3 COPD results in former smokers, the analyst tells investors in a research note. The firm says that wWhile Aerify-1 met its primary endpoint in both dosing arms, Aerify-2 failed to achieve statistical significance improvement at week 52. While Aerify-1 was positive, the path to approval is unclear, contends Citi. Confident Investing Starts Here:

Arvinas downgraded to Market Perform from Outperform at Leerink
Arvinas downgraded to Market Perform from Outperform at Leerink

Business Insider

time2 hours ago

  • Business Insider

Arvinas downgraded to Market Perform from Outperform at Leerink

Leerink analyst Andrew Berens downgraded Arvinas (ARVN) to Market Perform from Outperform with a price target of $9, down from $10, after the company presented full results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant in second-line HR+/HER2- metastatic breast cancer patients. The firm says that while the full presentation demonstrates the drug is active in patients with ESR1 mutations and likely approvable, it is not convinced vepdeg is best-in-class. Further, a number of key uncertainties in the rapidly evolving treatment paradigm for ESR1m breast cancer landscape have emerged, the analyst tells investors in a research note. Leerink 'gradually tempered the ESR1m rate in second-line from 30% to 15% to reflect potential impact from the SERENA-6 data, as well as ongoing first-line oral SERD trials, lowering its assumed worldwide peak vepdeg sales to $416M from $576M.

AstraZeneca, Daiichi announce results from three trials on DATROWAY
AstraZeneca, Daiichi announce results from three trials on DATROWAY

Business Insider

time4 hours ago

  • Business Insider

AstraZeneca, Daiichi announce results from three trials on DATROWAY

Results from three trials continue to demonstrate the potential of DATROWAY in combination with various immunotherapies to improve outcomes in patients with non-small cell lung cancer, NSCLC, across multiple stages of the disease. These results from TROPION-Lung02, TROPION-Lung04 and NeoCOAST-2 were presented at the 2025 American Society of Clinical Oncology Annual Meeting. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate, ADC, discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (AZN). In 42 patients receiving first-line doublet DATROWAY plus pembrolizumab, an objective response rate of 54.8% was observed. In 54 patients receiving first-line triplet DATROWAY plus pembrolizumab and platinum chemotherapy, an ORR of 55.6% was observed. This analysis included patients enrolled during the dose escalation phase of the trial, where 4.8% and 40.7% of patients treated with the doublet and triplet regimens, respectively, received DATROWAY at a dose of 4 mg/kg versus 6 mg/kg. First results from cohort 5 of the TROPION-Lung04 phase 1b trial, presented during a poster session on Saturday, May 31, showed DATROWAY plus AstraZeneca's PD-1/TIGIT bispecific antibody rilvegostomig as a first-line treatment demonstrated an ORR of 57.5%, including one complete response and 22 partial responses in 40 patients with advanced or metastatic NSCLC. A disease control rate of 95% was seen. Final results from Arm 4 of the NeoCOAST-2 phase 2 platform trial evaluating neoadjuvant DATROWAY plus AstraZeneca's anti-PD-L1 therapy IMFINZI and single-agent platinum chemotherapy were presented during a poster session on Saturday, May 31 and showed the combination demonstrated a pathologic complete response rate of 35.2%

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store